USFDA approves Inclisiran to lower LDL cholesterol - Video
|
Overview
US Food and Drug Administration has approved inclisiran (Leqvio; Novartis) for lowering LDL cholesterol levels.
Inclisiran is a small interfering RNA (siRNA) therapy which has been approved as an adjunct to diet and maximally tolerated statin therapy in patients with atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (FH) with LDL cholesterol levels that are still too high.
For more details, check out the full story on the link below:
FDA approves inclisiran to lower LDL cholesterol and keep it low with two doses a year
Speakers
Roshni Dhar, a Mass com graduate with a soft corner for health happenings, joined Medical Dialogues as a news anchor in 2021. Inspired by her mother who is a gynaecologist, she likes to keep herself and the world updated on the occurring in the medical field. She covers various aspects of health news for MDTV at Medical Dialogues. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751
